| Literature DB >> 35802528 |
Liuxin Zhang1, Mengting Zhang2, Min Wang2, Minxian Wang2, Ru Zhang2, Hongliang Wang3, Wei Zhang4, Yajie Ding2, Jie Wang2.
Abstract
BACKGROUND: Various noninvasive tools based on anthropometric indicators, blood lipids, and liver enzymes, etc. have been developed to screen for nonalcoholic fatty liver disease (NAFLD), with different diagnostic performance and cutoff values among studies. We aimed to validate and compare eight NAFLD-related models developed by simple indicators and to define their cutoff values in Chinese community population.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35802528 PMCID: PMC9273302 DOI: 10.1097/MEG.0000000000002399
Source DB: PubMed Journal: Eur J Gastroenterol Hepatol ISSN: 0954-691X Impact factor: 2.586
Characteristics of nonalcoholic fatty liver disease-related models
| Model | Full name | Country, year | Formula |
|---|---|---|---|
| FLI [ | Fatty Liver Index | Italy, 2006 | FLI = e 0.953 × ln TG + 0.139 × BMI + 0.718 × ln (GGT) + 0.053 × WC − 15.745)/(1 + e 0.953 × ln TG + 0.139 × BMI + 0.718 × ln (GGT) + 0.053 × WC − 15.745) × 100 |
| FLD [ | Fatty liver disease index | China, 2013 | FLD index = BMI + TG + 3 (ALT/AST ratio) + 2HG (presence of HG, HG = 1; absence of HG, HG = 0) |
| ZJU [ | Zhejiang University index | China, 2015 | ZJU index = BMI + FPG + TG + 3 ALT/AST ratio + 2 (if female) |
| LAP [ | Lipid accumulation product | Italy, 2010 | LAP (male) = (WC – 65) × TG |
| CAP [ | Regression formula of controlled attenuation parameter | China, 2018 | CAP = 113.163 + 0.252 × ALT + 6.316 × BMI |
| WHtR [ | Waist-to-Height Ratio | Japan, 1995 | WHtR = WC/height × 100 |
| TyG [ | Triglyceride and glucose index | Mexico, 2008 | TyG = ln[(TG × FPG)/2] |
| VAI [ | Visceral adiposity index | Italy, 2012 | VAI (male) = (WC/(39.68 + (1.88 × BMI))) × (TG/1.03) × (1.31/HDL-C) |
ALT, alanine aminotransferase; AST, aspartic transaminase; BP, blood pressure; DM, diabetes mellitus; FPG, fasting plasma glucose; GGT, gamma-glutamyl transpeptidase; HG, hyperglycemia; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; TB, total bilirubin; TC, total cholesterol; WC, waist circumference; platelet count.
Characteristics of the study population and comparison between subjects with and without nonalcoholic fatty liver disease
| Variables | All participants ( | Non-NAFLD ( | NAFLD ( |
| |
|---|---|---|---|---|---|
| Male ( | 2387 (73.2) | 1378 (65.9) | 1009 (86.3) | 158.887 | <0.001[ |
| Age (years) | 40.59 ± 9.30 | 39.61 ± 9.24 | 42.34 ± 9.15 | −8.1 | <0.001[ |
| WC (cm) | 83.01 ± 9.47 | 79.65 ± 8.55 | 89.03 ± 7.93 | −31.48 | <0.001[ |
| BMI (kg/m2) | 23.46 ± 2.97 | 22.37 ± 2.61 | 25.42 ± 2.54 | −32.28 | <0.001[ |
| SBP (mmHg) | 125.45 ± 15.34 | 122.37 ± 14.31 | 130.97 ± 15.59 | −15.54 | <0.001[ |
| DBP (mmHg) | 75.88 ± 10.46 | 73.73 ± 9.66 | 79.73 ± 10.74 | −15.85 | <0.001[ |
| TC (mmol/L) | 4.60 ± 0.86 | 4.49 ± 0.81 | 4.79 ± 0.90 | −9.44 | <0.001[ |
| TG (mmol/L) | 1.16 (0.84, 1.70) | 0.99 (0.75, 1.33) | 1.66 (1.19, 2.28) | −26.61 | <0.001[ |
| TBIL (mmol/L) | 13.86 (10.87, 17.84) | 13.92 (10.97, 18.00) | 13.73 (10.76, 17.66) | −1.16 | 0.248[ |
| DBIL (mmol/L) | 4.13 (3.35, 5.15) | 4.22 (3.37, 5.27) | 4.01 (3.29, 5.00) | −3.30 | 0.001[ |
| HDL-C (mmol/L) | 1.24 ± 0.32 | 1.33 ± 0.33 | 1.08 ± 0.25 | 24.11 | <0.001[ |
| LDL-C (mmol/L) | 2.70 ± 0.74 | 2.64 ± 0.71 | 2.81 ± 0.78 | −6.04 | <0.001[ |
| ALT (IU/L) | 19 (14, 29) | 16 (12, 23) | 26 (19, 38) | −23.33 | <0.001[ |
| AST (IU/L) | 19 (16, 23) | 18 (15, 21) | 21 (17, 25) | −14.83 | <0.001[ |
| GGT (IU/L) | 19 (13, 31) | 16 (12, 24) | 29 (19, 42) | −24.08 | <0.001[ |
| Scr (mmol/L) | 66.94 ± 13.29 | 65.69 ± 13.44 | 69.04 ± 12.76 | −6.96 | <0.001[ |
| FPG (mmol/L) | 4.75 (4.48, 5.05) | 4.70 (4.45, 4.97) | 4.85 (4.55, 5.21) | −9.16 | <0.001[ |
| FLI | 17.30 (6.79, 38.74) | 9.86 (4.58, 20.60) | 41.27 (23.94, 60.09) | −33.39 | <0.001[ |
| FLD | 28.34 ± 4.29 | 26.54 ± 3.46 | 31.58 ± 3.68 | −38.97 | <0.001[ |
| ZJU | 33.68 ± 4.22 | 31.95 ± 3.36 | 36.79 ± 3.80 | −36.35 | <0.001[ |
| TyG | 8.89 ± 2.97 | 7.87 ± 2.48 | 10.70 ± 2.93 | −27.88 | <0.001[ |
| CAP | 267.45 ± 20.73 | 259.44 ± 17.70 | 281.77 ± 17.87 | −34.43 | <0.001[ |
| LAP | 22.66 (12.88, 39.44) | 16.45 (9.72, 25.53) | 40.59 (27.18, 61.68) | −31.75 | <0.001[ |
| WHtR | 48.87 ± 4.90 | 47.10 ± 4.37 | 52.02 ± 4.15 | −31.37 | <0.001[ |
| VAI | 1.34 (0.85, 2.14) | 1.05 (0.72, 1.54) | 2.08 (1.37, 3.25) | −19.14 | <0.001[ |
Data are mean ± SD or median (interquartile range) for continuous variables; P values present comparisons between NAFLD patients and non-NAFLD subjects.
Chi-squared test.
Independent-samples T test.
Mann–Whitney U test.
ALT, alanine aminotransferase; AST, aspartic transaminase; CAP, controlled attenuation parameter; DBIL, direct bilirubin; DBP, diastolic blood pressure; FLD, fatty liver disease index; FLI, fatty liver index; FPG, fasting plasma glucose; GGT, gamma-glutamyl transpeptidase; HDL-C, high-density lipoprotein cholesterol; LAP, lipid accumulation product; LDL-C, low-density lipoprotein cholesterol; NAFLD, nonalcoholic fatty liver disease; platelet count; SBP, systolic blood pressure; Scr, serum creatinine; TBIL, total bilirubin; TC, total cholesterol; TG, triglyceride; TyG, triglyceride and glucose index; VAI, visceral adiposity index; WC, waist circumference; WHtR, waist-to-height ratio; ZJU, Zhejiang University index.
Areas under receiver operating characteristics curves of nonalcoholic fatty liver disease-related models for predicting nonalcoholic fatty liver disease
| Models | Total | Male | Female | ||||||
|---|---|---|---|---|---|---|---|---|---|
| AUC | SE | 95% CI | AUC | SE | 95% CI | AUC | SE | 95% CI | |
| FLI | 0.852 | 0.01 | 0.839–0.864 | 0.826 | 0.01 | 0.810–0.841 | 0.897 | 0.01 | 0.875–0.917 |
| FLD | 0.852 | 0.01 | 0.839–0.864 | 0.824 | 0.01 | 0.809–0.839 | 0.888 | 0.01 | 0.865–0.908 |
| ZJU | 0.847 | 0.01 | 0.835–0.860 | 0.826 | 0.01 | 0.810–0.841 | 0.892 | 0.01 | 0.869–0.911 |
| LAP | 0.835 | 0.01 | 0.822–0.847 | 0.804 | 0.01 | 0.788–0.820 | 0.879 | 0.01 | 0.856–0.900 |
| CAP | 0.823 | 0.01 | 0.810–0.836 | 0.794 | 0.01 | 0.778–0.810 | 0.847 | 0.02 | 0.821–0.870 |
| WHtR | 0.797 | 0.01 | 0.783–0.811 | 0.768 | 0.01 | 0.751–0.785 | 0.812 | 0.02 | 0.784–0.837 |
| TyG | 0.792 | 0.01 | 0.777–0.806 | 0.761 | 0.01 | 0.743–0.778 | 0.834 | 0.02 | 0.807–0.859 |
| VAI | 0.791 | 0.01 | 0.777–0.805 | 0.769 | 0.01 | 0.751–0.786 | 0.837 | 0.02 | 0.810–0.861 |
Fig. 1.Areas under receiver operating characteristic curves of nonalcoholic fatty liver disease-related models in total, male and female population.
Fig. 2.Comparison of Receiver-operating characteristic (ROC) curves of the NAFLD-related models for the detection of NAFLD in the validation. (a) Comparison of ROCs in total population. (b) Comparison of ROCs in male population. (c) Comparison of ROCs in female population. Comparisons of the areas under receiver operating characteristic (AUC) curves between FLI and other indexes were performed by the method of DeLong et al. NAFLD, nonalcoholic fatty liver disease.
Fig. 3.Decision Curve Analysis for NAFLD Screening. NAFLD, nonalcoholic fatty liver disease.
Cutoff values and diagnostic accuracy of nonalcoholic fatty liver disease-related models in total, male and female population
| Model | Total | Male | Female | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Cutoff[ | Sensitivity (%) | Specificity (%) | Cutoff[ | Sensitivity (%) | Specificity (%) | Cutoff[ | Sensitivity (%) | Specificity (%) | |
| FLI | 20.6 | 85.3 | 75.1 | 25.3 | 78.4 | 72.4 | 8.4 | 88.1 | 78.2 |
| 30 | 66.1 | 84.9 | 30 | 71.2 | 78.4 | 30 | 34.1 | 97.9 | |
| 60 | 24.9 | 96.9 | 60 | 28 | 95.3 | 60 | 5.4 | 100 | |
| FLD | 28.7 | 79.6 | 75.2 | 29.0 | 80.0 | 70.0 | 26.1 | 88.2 | 75.6 |
| ZJU | 33.7 | 80.6 | 73.8 | 33.7 | 80.4 | 69.3 | 33.7 | 82.6 | 82.3 |
| LAP | 26.9 | 75.6 | 77.7 | 26.9 | 77.3 | 71.1 | 19.7 | 84.4 | 77.9 |
| CAP | 269.7 | 75 | 74.2 | 272.4 | 72.2 | 71.6 | 259.9 | 79.5 | 77.1 |
| WHtR | 49.7 | 72.5 | 72.5 | 49.4 | 76.6 | 63.6 | 45.5 | 91.9 | 56.3 |
| TyG | 9.1 | 71.9 | 73.1 | 9.1 | 72.5 | 67.7 | 8.9 | 70.2 | 82.1 |
| VAI | 1.6 | 68.3 | 76.1 | 1.7 | 62.9 | 78.3 | 1.6 | 71.2 | 81.8 |
Apart from 30 to 60 cutoff points of FLI, optimal cutoff values of all scores were determined by the maximum of Youden index.
CAP, controlled attenuation parameter; FLD, fatty liver disease index; FLI, fatty liver index; LAP, lipid accumulation product; NAFLD, nonalcoholic fatty liver disease; TyG, triglyceride and glucose index; VAI, visceral adiposity index; WHtR, waist-to-height ratio; ZJU, Zhejiang University index.